期刊文献+

盐酸表柔比星联合奥沙利铂对肝癌HepG2细胞凋亡的抑制作用 被引量:8

Inhibitory effect of epirubcin hydrochloride co-treated with oxaliplatin in the apoptosis of HepG2 cells
下载PDF
导出
摘要 目的:探讨盐酸表柔比星联合奥沙利铂对肝癌细胞HepG2的抑制作用。方法:盐酸表柔比星和奥沙利铂单独及联合给药用MTT法测定HepG2细胞的增殖,用Hoechst 33258染色法检测细胞核凋亡情况,用DNA ladder检测DNA的裂解情况。结果:人肝癌HepG2细胞经奥沙利铂、盐酸表柔比星以及两者联合作用后,在不同时间、不同浓度均能出现细胞抑制作用,并且均呈现剂量-时间依赖效应,与单药组相比,联合用药组抑制率明显增高,q值大部分为0.85~1.15,呈现明显的相加作用,在(35+5)μg/mL组作用24h,(20+2)μg/mL组作用48、72h时两组实验组q值<0.85,出现拮抗作用。(25+3)μg/mL组作用24h为最佳作用时间和作用浓度。结论:奥沙利铂及盐酸表柔比星对肝癌HepG2细胞有增殖抑制及促凋亡作用,两药联合作用表现为相加作用,其机制需进一步研究。 AIM:To investigate the inhibitory effect of epirubcin hydrochloride in combination use with oxaliplatin(L-OHP) on the hepatocellular carcinoma cells HepG2.METHODS:The inhibitory effect of epirubicin hydrochloride together with L-OHP on the growth of human hepatic carcinoma cell line HepG2 in vitro was evaluated by MTT assay.The apoptosis of nucleus was detected by Hoechst33258staining.The degradation of DNA was evaluated by DNA ladder.RESULTS:Oxaliplatin and epirubicin hydrochloride both inhibited the proliferation of HepG2cells,it presented addictive inhibition effect when two medicine combined(q value was in 0.85-1.15).CONCLUSION:Oxaliplatin and epirubicin hydrochloride both inhibited the proliferation of HepG2cells and promoted apoptosis,combination of these medicine presented addictive inhibition effect,however,the mechanism was unclear.
出处 《中国临床药理学与治疗学》 CAS CSCD 2013年第5期490-494,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 中南大学中央高校基本科研业务资助(2011QZT206)
关键词 肝癌 奥沙利铂 盐酸表柔比星 细胞凋亡 Hepatocellular carcinoma Oxaliplatin Epirubicin hydrochloride Apoptosis
  • 相关文献

参考文献12

二级参考文献34

  • 1张燕,左国庆,汤为学.奥沙利铂对人肝癌细胞株HepG2体外增殖的影响[J].中华肝脏病杂志,2004,12(6):374-375. 被引量:40
  • 2李长政,王志强,方翼.奥曲肽对肝癌细胞SMMC-7721增殖的抑制作用[J].中国临床药理学与治疗学,2004,9(8):919-921. 被引量:1
  • 3Min Lian,Ying Liu,Shun-Zhang Yu,Geng-Sun Qian,Shu-Guang Wan,Kenneth R Dixon.Hepatitis B virus x gene and cyanobacterial toxins promote aflatoxin B_1-induced hepatotumorigenesis in mice[J].World Journal of Gastroenterology,2006,12(19):3065-3072. 被引量:14
  • 4Ji XQ, Ruan XJ, Chen H, et al. Somatostatin analogues in advanced hepatocellular carcinoma: An updated systematic review and meta-analysis of randomized controlled trials[J]. Med Sci Monit,2011, 17(8) :169--176.
  • 5Reynaert H, Rombouts K, Vandermonde A, et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma [J]. Gut,2004,53(8) :1180-1189.
  • 6Borbath I, Strkel P. Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models [J]. Acta Gastroenterol Belg,2011,74(1) :34--44.
  • 7Autschbach F, Palou E, Mechtersheimer G, et al. Expression of the membrane protein tyrosine phosphatase CD148 in human tissues [J] . Tissue Antigens,1999,54(11) :485--498.
  • 8Florio T, Arena S, Thellung S, et al. The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PCC13 thyroid cell proliferation [J] . Mol Endoerinol,2001,15(12) :1838--1852.
  • 9Massa A,Barbieri F, Aiello C, et al. The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation [J]. Biol Chem, 2004,279 (7) : 29004-- 29012.
  • 10Massa A,Barbieri F, Aiello C,et al. The phosphotyrosine phosphatase etamediates soraatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2 [J]. Ann NY Acad Sci, 2004,1030 (12) :264--274.

共引文献27

同被引文献109

  • 1张燕,左国庆,汤为学.奥沙利铂对人肝癌细胞株HepG2体外增殖的影响[J].中华肝脏病杂志,2004,12(6):374-375. 被引量:40
  • 2冯觉平,于世英,王亚萍,袁响林,李敏,方静.奥沙利铂对肝癌细胞HepG2生物学行为的影响[J].肿瘤,2010,30(9):753-757. 被引量:3
  • 3何剑英.表柔比星与多柔比星治疗老年非霍奇金淋巴瘤对比观察[J].山西职工医学院学报,2005,15(4):41-41. 被引量:5
  • 4.日本抗生物质医药品基准解说[S].[S].,1998.443-445.
  • 5日本抗生物质医药品基准解说[S].1993:106.
  • 6严鹏伟.MDR1基因C3435T位点单核苷酸多态性与乳腺癌术后含表柔比星辅助化疗方案的疗效观察和预后因素分析[D].南京:南京医科大学第一临床医学院,2010.
  • 7Shukui Qin,Yuxian Bai,Ho Yeong Lim,Sumitra Thongprasert,Yee Chao,Jia Fan,Tsai-Shen Yang,Vajarabhongsa Bhudhisawasdi,Won Ki Kang,Yu Zhou,Jee Hyun Lee,Yan Sun.Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia[J].Journal of Clinical Oncology.2013(28)
  • 8Peng Xiu,Xuesong Dong,Xiaofeng Dong,Zongzhen Xu,Huaqiang Zhu,Feng Liu,Zheng Wei,Bo Zhai,Jagat R. Kanwar,Hongchi Jiang,Jie Li,Xueying Sun.Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma[J].Cancer Sci.2013(3)
  • 9Olivier Mir,Romain Coriat,Pascaline Boudou-Rouquette,Stanislas Ropert,Jean-Philippe Durand,Anatole Cessot,Vincent Mallet,Philippe Sogni,Stanislas Chaussade,Stanislas Pol,Fran?ois Goldwasser.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib[J].Medical Oncology.2012(4)
  • 10Alejandro Forner,Josep M Llovet,Jordi Bruix.Hepatocellular carcinoma[J].The Lancet.2012(9822)

引证文献8

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部